2025-03-26FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNETDrug Cabometyx (cabozantinib) · VEGFR inhibitorConditionsEndocrineGastrointestinal
2023-11-08FDA approves fruquintinib in refractory metastatic colorectal cancerTrials FRESCO-2, FRESCODrug Fruzaqla (fruquintinib) · VEGFR inhibitorConditionGastrointestinal
2019-01-14FDA approves cabozantinib for hepatocellular carcinomaTrial CELESTIALDrug CABOMETYX (cabozantinib) · VEGFR inhibitorConditionGastrointestinal